EP2543384A3

Treatment of conditions involving demyelination

Abstract

The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrcoyte progenitor cells with an ErbB2 binding agent.

Term

Projected expiry 1 December 2026.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

Every citation, both ways

Citations
DocumentRelationOfficeCited during
WO2004085648A2CitesWorld Intellectual Property Organization (WIPO)Search report
WO2006002437A2CitesWorld Intellectual Property Organization (WIPO)Search report